Arcturus Therapeutics (NASDAQ:ARCT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Arcturus Therapeutics (NASDAQ:ARCT) from a sell rating to a hold rating in a research report released on Saturday morning.

Several other equities research analysts have also issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Wednesday, October 8th. HC Wainwright lowered their price target on Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a report on Tuesday, November 11th. BTIG Research dropped their price target on Arcturus Therapeutics from $48.00 to $23.00 and set a “buy” rating for the company in a research report on Wednesday, October 22nd. Leerink Partners cut their price objective on Arcturus Therapeutics from $63.00 to $54.00 and set an “outperform” rating for the company in a report on Friday, August 22nd. Finally, Piper Sandler decreased their price objective on shares of Arcturus Therapeutics from $140.00 to $72.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 11th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $36.00.

Arcturus Therapeutics Trading Down 7.0%

Shares of Arcturus Therapeutics stock opened at $6.76 on Friday. The firm has a market capitalization of $192.05 million, a P/E ratio of -2.75 and a beta of 2.47. The business’s fifty day simple moving average is $15.96 and its 200 day simple moving average is $14.56. Arcturus Therapeutics has a 12 month low of $6.72 and a 12 month high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last released its earnings results on Monday, November 10th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.60. The firm had revenue of $17.15 million during the quarter, compared to the consensus estimate of $17.47 million. Arcturus Therapeutics had a negative net margin of 68.35% and a negative return on equity of 28.68%. Analysts predict that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of hedge funds have recently made changes to their positions in ARCT. CANADA LIFE ASSURANCE Co boosted its stake in shares of Arcturus Therapeutics by 27.5% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 1,567 shares in the last quarter. Brevan Howard Capital Management LP purchased a new stake in Arcturus Therapeutics during the third quarter valued at about $518,000. Bank of America Corp DE boosted its position in Arcturus Therapeutics by 112.0% during the third quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after buying an additional 327,626 shares during the period. Two Sigma Investments LP grew its stake in shares of Arcturus Therapeutics by 3.3% during the third quarter. Two Sigma Investments LP now owns 89,219 shares of the biotechnology company’s stock valued at $1,644,000 after buying an additional 2,857 shares during the last quarter. Finally, Kennedy Capital Management LLC increased its holdings in shares of Arcturus Therapeutics by 95.5% in the third quarter. Kennedy Capital Management LLC now owns 22,825 shares of the biotechnology company’s stock worth $421,000 after buying an additional 11,151 shares during the period. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.